China's pharmaceutical circulation industry is showing four development trends

[pharmaceutical network market analysis 】In recent years, the state has issued a series of policy documents, such as the outline of "healthy China 2030" plan, the plan for deepening the reform of medical and health system during the 13th five year plan, and the national development plan for drug distribution industry (2016-2020), to promote the drug distribution industry to actively implement the policy requirements of medical reform and strive to explore innovative development thinking Under the influence of many factors, at present, the development of China's pharmaceutical circulation industry also stands on a new starting point With the continuous expansion of the industry scale and the rapid development of new models such as medicine e-commerce, and with the deepening of China's pharmaceutical reform, China's pharmaceutical circulation industry will develop in a more healthy direction in the future Whole process management of drug quality Previously, the State Food and Drug Administration issued guidance on the construction of drug information traceability system (gjjg [2018] No 35) and notice on strengthening drug supervision during the pilot period of centralized drug purchase and use (gjjg [2018] No 57), which clearly pointed out that operating enterprises and users should cooperate with drug listing license holders and manufacturers In the future, the regulatory authorities will strengthen the whole process management including drug circulation and use With the increasing use of clinical Biopharmaceutics, the whole life cycle quality management of drugs, including storage and distribution, will be paid more and more attention With the upgrading of retail drugstores and the accelerated development of medicine e-commerce, with the improvement of consumption level and health concept of domestic residents in the future, the overall expansion of demand for medicine under the aging population will further expand the scale of China's medicine circulation industry At the same time, under the promotion of favorable policies, the industry concentration in the field of pharmaceutical circulation will continue to improve in 2020, and the competition among enterprises, especially among leading enterprises, will become increasingly fierce In addition, with the enabling of information technology, the logistics service of China's pharmaceutical distribution supply chain will be more perfect The structure of drug retail business and the way of competition will also accelerate to change Special drug (DTP) pharmacies, chronic disease pharmacies and other professional characteristic pharmacies will continue to emerge, and smart pharmacies will become a new highlight of transformation and upgrading Under the impetus of "Internet plus", the potential development of medical and electronic business is huge The development of medical Internet will also bring the ecological development of health industry and build a new intelligent health ecosystem of pharmaceutical circulation industry Increasing market concentration In recent years, with the implementation of the policy of medicine separation, medicine Zero addition, control medicine proportion and two vote system, the development of medicine circulation industry has gradually become standardized Some small and medium-sized medicine circulation enterprises are gradually being acquired or withdrawn from the market The whole industry is facing the general trend of reshuffle and integration, which is very beneficial to the development and growth of leading enterprises At present, in the pharmaceutical circulation market, the national leader has basically formed, and the pattern is relatively stable And the regional leading enterprises have great opportunities and great growth space In the future, the industry competition pattern of "national leader + local separation" will gradually form, which is the inevitable trend of the development of pharmaceutical logistics industry The service ability of the third party logistics will continue to improve With the deepening of the reform of China's pharmaceutical circulation system, and the increasing trend of specialization, the third party pharmaceutical logistics has gradually received widespread attention both inside and outside the industry, and has shown a good momentum of development The two ticket system and other new policies give more opportunities to the growth of the third-party logistics, so it is an inevitable trend for more enterprises to participate in the drug distribution business in the future However, the third-party logistics service in China is not very perfect, and the ability of service management needs to be improved In the fierce competition, only by improving their own service ability can enterprises maintain their advantages in the competition In addition, in the face of the fierce competition of the third-party logistics platform, downstream customers' demands for cost and efficiency and management improvement, the trend of pharmaceutical supply chain innovation in 2020 will continue to progress The supply chain continues to expand horizontally No matter the pharmaceutical distribution enterprises or pharmaceutical logistics enterprises, they will certainly move towards the supply chain in the future, that is, the collaborative development of upstream and downstream It is understood that foreign pharmaceutical distribution enterprises are highly coordinated with production enterprises What production enterprises produce is what circulation enterprises tell him, which is the integrated development of supply chain At present, domestic enterprises are facing new changes brought about by the "two vote system" Earlier, the market model of "channel is king" is constantly challenged In order to continue its glory, commercial enterprises must provide more value-added services for upstream industrial enterprises, partners and downstream end customers in the industrial chain, in addition to horizontal expansion in network construction, cost management and other aspects